7 Lessons1h 17m

PGT-A Genetic Screening

Giving you the full picture: where it helps, where it doesn’t, and how you might think about this expensive add-on based on your specific priorities.

Start Learning
PGT-A Genetic Screening
62k took this course
Start Learning

Experts you'll learn from

Dr. Chantel Cross

Associate Director
Johns Hopkins School of Medicine

Dr. Eve Feinberg

Medical Director, REI
Northwestern Medicine

Dr. Eric Forman

Medical Director
Columbia University Medical Center

Dr. Nalini Kaul (Mahajan)

Director, Mother & Child Hospital
Scientific Director, Ferticity Fertility Clinics
India

Dr. Christian M. Becker

Co-Director, Oxford BSGE Endometriosis Centre
Associate Professor, Oxford University
United Kingdom

Dr. Zev Williams

Division Chief
Columbia University

Dr. Valerie Baker

Division Chief
Johns Hopkins School of Medicine

Dr. Caroline McCaffrey

Laboratory Director
NYU School of Medicine

Dr. Owen Davis

Former President, ASRM
Associate Director, REI
Weill Cornell Medical Center

Dr. Jamie Grifo

Medical Director
NYU School of Medicine

Dr. Robert Z. Spaczynski

Uniwersytet Medyczny w Poznaniu
Centrum Ginekologii, Położnictwa i Leczenia Niepłodności Pastelova w Poznaniu

Professor
Poznan University School of Medicine
Poland

Dr. Ruben Alvero

Division Director, REI
Stanford University Medical Center

Dr. William Schoolcraft

Founder & Medical Director
CCRM Colorado

Dr. Lubna Pal

Fellowship Director
Yale School of Medicine

Dr. Viji Sundaram

Reproductive Fertility Specialist
Kaiser Permanente Centers for Reproductive Health

MUDr. Štěpán Machač

Vedoucí lékař skupiny FutureLife
Předseda výboru sekce asistované reprodukce ČGPS

Dr. Stepan Machac

Chief Medical Officer, FutureLife International
Chairman, Czech IVF Society

Dr. Brian Levine

Practice Director
CCRM New York

Dr. Alan Copperman

Vice Chairman, OBGYN
Mount Sinai Medical Center

Amber Kaplun, MS, CGC

Lead Genetic Counselor, IVI RMA America

"Full refund within 30 days, no questions asked"
Eligible for FSA/HSA
$95

Course syllabus

  1. 5 min
    Done
    1. PGT-A Course Objectives
  2. 8 min
    Done
    1. The Basics of PGT-A
    2. Avoiding Transfer of Abnormal Embryos
    3. Predictive Power of Euploid Embryos
    4. What the PGT-A Process Entails
    5. Pro Tips
  3. 10 min
    Done
    1. Less Pregnancy Loss
    2. More Single Embryo Transfer
    3. Better Family Planning
    4. Cost Savings
    5. Is PGT-A an Obvious Win?
    6. Pro Tips
  4. 8 min
    Done
    1. Why Mosaicism Matters
    2. A Simple Way to Wrap Your Head Around Mosaicism
    3. Will Your Doctor Tell You About Mosaicism If You’re Affected?
    4. How Often Does Mosaicism Actually Exist
    5. Developing a Transfer Hierarchy With Mosaic Embryos
    6. If You’re Thinking About Transferring a Mosaic Embryo
    7. The Need to Consult a Genetic Counselor
    8. Pro Tips
  5. 19 min
    Done
    1. Introducing the Anti-PGT-A Arguments
    2. Argument 1: Biopsying an Embryo Has Risks
    3. Argument 2: PGT-A Test Inaccuracy Could Lead Us to Discard Good Embryos
    4. Argument 3: PGT-A Is Wrong For Older Patients
    5. Argument 4: PGT-A Is Wrong for Younger Patients
    6. Argument 5: PGT-A’s Benefits Are Inaccurately Marketed
    7. Argument 6: PGT-A Is Not Worth the Money
    8. Pro Tips
  6. 8 min
    Done
    1. What Does PGT-A Cost?
    2. Components of Cost
    3. Questions of Value
    4. Patient Example 2: 42-Year-Old Woman With Four Embryos, Zero Are Euploid
    5. Pro Tips
  7. 18 min
    Done
    1. Introduction
    2. Overview of PGT-M & PGT-SR
    3. A Closer Look at PGT-M
    4. A Closer Look at PGT-SR
    5. Selecting an Embryo for Transfer
    6. Limitations of PGT-M and PGT-SR
    7. Other Considerations About Testing

What you'll learn

We cover the benefits of PGT-A and their magnitude. We dissect the subject of mosaicism and how it helps to construct a hierarchy of which embryos to transfer. We train patients to ask the relevant questions of their clinic, clinic’s laboratory, and reference laboratory before signing on to do PGT-A. Finally, we address the risk around damage during biopsy, how often useful embryos are being discarded, and how the investment in PGT-A looks for women of different ages.